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Abstract: Peptide dendrimers are a novel class of macromolecules of emerging interest with 
the potential of delayed renal clearance due to their molecular size and enhanced activity due to 
the multivalency effect. Difficulties in the synthesis of homogeneous dendrimers carrying well-
structured peptides have largely hampered progress in this field. In this work, an active analogue 
of the disulfide rich chi-conotoxin χ-MrIA, a norepinephrine reuptake (NET) inhibitor, was 
grafted onto a polylysine dendron. Dendron decoration was achieved by employing copper 
catalyzed alkyne-azide cycloaddition (CuAAc) in combination with the use of hydrophilic PEG 
linkers, leading to homogenous 4- and 8-mer χ-MrIA dendrimers with molecular weights from 8 
KDa to 22 KDa. These dendrimers were investigated for their impact on peptide secondary 
structure, in vitro functional activity and potential anti-allodynia function in vivo. NMR studies 
showed that the χ-MrIA-peptide analogue tertiary structure was identical to the parent peptide in 
the two dendrimers. In a functional norepinephrine transporter reuptake assay, χ-MrIA 
dendrimers showed slightly increased potency relative to the azido-PEGylated χ-MrIA analogues 
but no improvement compared to the parent peptide χ-MrIA. In contrast to χ-MrIA, no anti-
allodynic action was observed when χ-MrIA dendrimers were administered intrathecally in a rat 
model of neuropathic pain, suggesting that the larger dendrimer structure is unable to diffuse 
through spinal column tissue to reach the NET transporter.  
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Dendrimers with polyvalent structures have been extensively investigated in biomedicine in the 
past few decades.1, 2 In particular, they are widely regarded as useful carriers for small molecule 
drugs and gene delivery though bioactive peptides have been less exploited.3, 4 Peptides by 
themselves represent a large class of bioactive molecules and have emerged as prospective drug 
candidates for various diseases.5, 6 By integrating the merits of dendrimers with bioactive 
peptides, dendrimeric peptides have produced diverse synergistic effects, including a 
multivalency effect that enhances the avidity of the peptide ligand while delaying renal clearance 
due to its increased molecular size.7, 8, 9, 10 Many synthetic approaches are now available for 
generating peptide dendrimers either in a stepwise manner (divergent) or by ligation of pre-
purified segments (convergent).11, 12 Nevertheless, the synthesis of fully decorated dendrimers 
with multiple copies of the peptide ligand, particularly with disulfide bond-containing peptides, 
has proven to be challenging.13 Several conjugation strategies such as peptide coupling 
chemistry,14 thiol-maleimide chemistry,15 copper catalyzed alkyne-azide cycloaddition10 and 
oxime ligation16 have been applied in the design and synthesis of oxidatively folded peptide 
dendrimers, though at most tetramer decorated dendrimers have emerged with incomplete 
decoration14 and disulfide bond shuffling issues have been observed.15 Fully decorated 
dendrimers containing more than 4 copies of cysteine-rich peptides remain thus far unreported. 
Disulfide bonds are a common posttranslational modification and they are functionally important 
in bioactive peptides and proteins.17 Disulfide bridges are highly prevalent in peptide toxins 
secreted in animal venoms, e.g. conotoxins.18 Conotoxins are cysteine-rich bioactive peptides 
from cone snails that act on a wide variety of ion channels, G-protein coupled receptors 
(GPCR’s) and transporters with exquisite potency and selectivity.19, 20, 21 Of particular interest is 
χ-conotoxin MrIA (χ-MrIA), which contains 2 disulfide bonds arranged in a "ribbon" structure 
(1-4, 2-3 connectivity) and acts as a selective inhibitor of the norepinephrine transporter (NET).22 
These χ-conotoxins has been translated into the clinic for the treatment of chronic neuropathic 
pain.23, 23, 24 In addition, NET inhibitors have the potential to treat a number of neurological 
conditions, such as depression,25 schizophrenia,26 anxiety27 and other psychotic disorders.26 An 
alanine scan28 of C-terminally amidated χ-MrIA (NGVCCGYKLCHOC-NH2, 1-4, 2-3 
connectivity) and intensive SAR work20 has shown that the NET-modulating pharmacophore is 
mainly located within the inter-cysteine GYKL loop sequence and this has eventually lead to the 
development of peptidomimetics of χ-MrIA.29 It was evident from this earlier work that any 
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small structural changes in the pharmacophore significantly interfere with the biological 
activity.20 Thus to maintain dendrimers with bioactivity demands that the peptide secondary 
structure remains undisturbed. The previous structure–activity relationship (SAR) studies also 
revealed that the N-terminal of χ-MrIA is not located in the pharmacophoric region, and thus 
provides an ideal ligation site for linkage to a dendrimer platform.28 Furthermore, it was shown 
that hydroxyproline (position 11) can be substituted by proline28 and the asparagine residue 
responsible for unwanted aspartimide formation30 can be truncated31 without altering the hNET-
bioactivity of the peptide.  
The clinical χ-MrIA analogue (Xen2174) was developed for intrathecal injection and its duration 
of action was largely determined by the clearance rate from the IT space into the plasma.[32] 
Given the polyvalent structure and large molecular size, a dendrimeric formulation of χ-MrIA 
was anticipated to be an interesting synthetic target to modulate the pharmacokinetic properties. 
In this study, we undertook the synthesis of χ-MrIA dendrimers of differing size PEG spacers 
with molecular weights ranging from 8 KDa to 22 KDa and further investigated their structural 
and functional features. Initially, χ-MrIA dendrimers carrying 4 and 8 copies of the χ-MrIA 
analogues ([Pro]11MrIA[2-13], 1) were successfully synthesized through the copper-catalyzed 
alkyne azide cycloaddition (CuAAc) reaction, based on the alkyne modified polylysine (PLL) 
dendrons (2 and 3, Figure 1) and azido-PEG-chain modified χ-MrIA analogues [N3-PEG(9 or 
24)-[Pro]11MrIA[2-13]-NH2  (4 and 5, Figure 2). The CuAAc reaction is a widely used strategy in 
peptide conjugation promising high efficiency and high selectivity.33, 34 Scheme 1 depicts the 
structure of an octameric χ-MrIA dendrimer 7 containing a lysine dendron core, PEG spacer 
units and a small charged (Gly-Arg4-Gly) tail we introduced to facilitate solubility and ease of 
mass spectrometric evaluation. The flexible polyethylene glycol segments of different lengths, 
approximately 35Å and 90Å respectively, were introduced between the peptide and dendron to 
reduce steric bulk and to herewith allow for sufficient dendron loading as well as increasing the 
solubility of the dendrimeric construct. The χ-MrIA dendrimers (6-8) were purified and 
characterized by HPLC coupled ESI-MS to confirm purity and homogeneity. Subsequently, their 
3-dimensional structures were determined by 2D NMR spectroscopy and their potency via an in 
vitro NE uptake cell-based assay and an in vivo pain model. These studies contribute to our 
understanding of multivalent peptide dendrimers. 
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Materials and methods 
Materials. All Nα-Fmoc-L-amino acids, Fmoc-L-Lys(Fmoc), N3-PEG-(9)-COOH, N3-PEG-
(24)-COOH and HBTU were purchased from IRIS Biotech (Marktredwitz, Germany). Rink 
Amide resin, DIEA, trifluoroacetic acid (TFA), DMF and piperidine were purchased from 
Auspep (Melbourne, Auatralia). DCM, ACN and diethyl ether were purchased from Merck 
(Melbourne, Australia). 5-azido-pentanoic acid was purchased from BACHEM Feinchemikalien 
AG (Bubendorf, Switzerland). HATU was imported from GL Biochem Ltd. (Shanghai, China). 
TBTA, 5-hexynoic acid, sodium azide, copper sulfate, sodium ascorbate, cooper iodide, copper 
wires, DMSO, Triisopropylsilane as well as all other reagents and solvents, were purchased from 
Sigma-Aldrich. (3H)NE, 96-well plate and Optiphase Supermix scintillant were all from Perkin 
Elmer. Water measuring 18.2 MΩ (ELGA, Melbourne, Australia) was used for all buffers for 
liquid chromatography. Screw-cap glass peptide synthesis reaction vessels with sintered glass 
filter frits were used throughout the synthesis.  
HPLC analysis and purification. Analytical RP-HPLC was performed on a Shimadzu LC-
20AD solvent delivery system equipped with a SIL-20A auto-injector and a SPD-20A UV/Vis 
detector using a Agilent Zorbax 300SB-C18 analytical column (300 Å, 5 μm, 150 mm × 4.6 mm). 
Data was recorded and processed with Shimadzu Class VP software. The absorbance was 
monitored by a UV detector at 214 nm and 254 nm, respectively. The HPLC solvent system was 
made as follows: solvent A was 0.05 % TFA in millpore water, while solvent B was 0.043% 
TFA in ACN/H2O (v/v: 90/10). For the peptide purification, two types of columns were used 
including GRACE-Vydac C18 column (300 Å, 10 μm, 250 mm × 22 mm) and Agilent Zorbax C18 
column (300 Å, 10 μm, 250 mm × 10 mm). The purification was carried out by preparative RP-
HPLC system using a Shimadzu LC-8A solvent delivery system. The absorbance was monitored 
at 214 nm and 230 nm with a Shimadzu SPD-10AV UV/Vis detector. 
Electrospray Mass Spectrometry (ESI-MS). PESCIEX API150EX mass spectrometer was 
coupled with HPLC to perform the peptide analysis. The Mass Spectrometry was operating in 
the positive ion mode with a declustering potential (DP) of 20 V, a focusing potential (FP) of 220 
V and a turbospray heater temperature of 350°C. 
Peptide Concentration Assessment. Peptide concentration was calculated based on peak area 
detected at 214 nm by analytical HPLC. A peptide (χ-MrIA) with known concentration identified 
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by amino acid analysis was used as the standard peptide. Molecular extinction coefficients were 
calculated according to the increments set up by Buck et al35 for the standard and sample 
peptides. By comparing the absorption data of the standard and samples.  
General protocols for Fmoc-SPPS synthesis. Peptides and dendrimers were assembled by 
Fmoc/tBu-based manual SPPS on a Rink amide resin (loading 0.71 mmol/g) using the 
HBTU/DIEA in situ neutralization protocol36 to activate the standard residues; treatment with 
30% piperidine/DMF (2 × 1 min) was used for Fmoc deprotection. Coupling was carried out 
with 4 equiv of Fmoc- amino acid, 4 equiv of HBTU, and 4 equiv of DIEA in DMF for a 
minimum of 10 min and the acylation efficiency was monitored by the quantitative ninhydrin 
test.37 For the couplings onto a proline residue, the efficiency was measured by the Isatin test.38 
N3-PEG(9)-COOH, N3-PEG(24)-COOH, and 5-hexynoic acid were coupled with 1.5 or 2 equiv 
of excess for a minimum of 1h. Cleavage of the peptide/dendrimer from resin was performed 
under standard conditions (TFA : triisopropylsilane : water, 90 : 5 : 5, 3 h). After the cleavage 
was complete, the mixture was filtered to remove the resin. The filtrate was transferred into cold 
peroxide free ether to precipitate the peptide. The supernatant was removed after centrifugation 
and the precipitate was dissolved in 50% Acetonitrile/water +0.0425%TFA and then lyophilized.  
Synthesis of first- and second- generation alkyne-dendrons 2 and 3 [GlyArg4Gly-
Lys[Lys]2[CO-(CH2)3-CCH]4, 2; GlyArg4Gly-Lys[Lys]2[Lys]4[CO-(CH2)3-CCH]8, 3] The 
sequence of GRRRRG was first assembled to the Rink amide resin. Then 4 equiv of excess 
Fmoc-L-Lys(Fmoc) acid per amine group was added to the coupling system to achieve dendrons 
with 4 and 8 final terminal amino groups. After that, 5-hexynoic acid, activated by 0.5 M 
HATU/DIEA, was coupled to the Lys-dendrons for 24h with 2 equiv excess per dendron-branch. 
After TFA cleavage, the crude products were purified with a preparative C18 column with 1 
%/min linear gradient of 10-60 % buffer B at a flow rate of 15 mL/min.  
Synthesis and oxidation of χ-MrIA analogues 4 and 5 [N3-PEG(9)-CO-NH-Gly-Val-Cys-Cys-
Gly-Tyr-Lys-Leu-Cys-His-Pro-Cys-NH2, 4; N3-PEG(24)-CO-NH-Gly-Val-Cys-Cys-Gly-Tyr-
Lys-Leu-Cys-His-Pro-Cys-NH2,  5 (Cysteine connectivity: 1-4, 2-3)] Reduced χ-MrIA analogues 
were synthesized through the standard Fmoc-SPPS method as above and the azido PEG spacer 
was attached to the amine group of the N-terminal glycine residue. Specifically, Fmoc-
Cys(Acm)-OH were coupled in position Cys3 and Cys12 while Fmoc-Cys(Trt)-OH were used in 
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position Cys4 and Cys9. N3-PEG(9)-COOH and N3-PEG(24)-COOH activated by HATU were 
coupled to the N-terminal glycine residue overnight. After TFA cleavage, the crude reduced 
peptides were dissolved in 0.1 M ammonium bicarbonate buffer at pH 8 to form the first 
disulfide bond between Cys4 and Cys9 employing air as oxidant. The oxidation products were 
subjected to preparative RP-HPLC system. The purified peptides were then treated with iodine (1 
mM) to remove the Acm protecting group and form the second disulfide bond between Cys3 and 
Cys12 simultaneously. After 1h, 0.1 M ascorbic acid was added to quench the reaction. The fully 
oxidized products were purified with a preparative C18 column with 1 %/min linear gradient of 
20-60 % buffer B at a flow rate of 15 mL/min.  
In-solution click reaction of alkyne-dendron (2, 3) and azido-PEG(n)-[Pro]11MrIA[2-13] (4, 
5) [GlyArg4Gly-Lys[Lys]2[CO-(CH2)3-1,2,3-triazole-PEG(9)-CO-NH-Gly-Val-Cys-Cys-Gly-
Tyr-Lys-Leu-Cys-His-Pro-Cys-NH2]4, 6; GlyArg4Gly-Lys[Lys]2[Lys]4[CO-(CH2)3-1,2,3-triazole-
PEG(24)-CO-NH-Gly-Val-Cys-Cys-Gly-Tyr-Lys-Leu-Cys-His-Pro-Cys-NH2]4, 7; GlyArg4Gly-
Lys[Lys]2[CO-(CH2)3-1,2,3-triazole-PEG(24)-CO-NH-Gly-Val-Cys-Cys-Gly-Tyr-Lys-Leu-Cys-
His-Pro-Cys-NH2]4, 8 [cysteine connectivity: 1-4, 2-3)] CuSO4 and sodium ascorbate were 
dissolved in water at a concentration of 0.1 M, respectively. Alkyne-dendrons 2 or 3 (Dendron 
concentration 5 μM) were dissolved in DMF. Azido-PEG(n)-[Pro]11MrIA[2-13] (4 or 5; 2 
equiv/branch) was weight and the solution of CuSO4 (0.2 equiv/branch) and TBTA ligand (0.2 
equiv/branch) was added. The mixture was degassed with nitrogen for 15 min and the solution of 
sodium ascorbate (0.5 equiv/branch) was added to the sealed reaction vessel to initiate the click 
reaction. The reaction was performed overnight at room temperature and the resulting reaction 
products were purified with a Zorbax semi-preparative C18 column with 0.5 %/min linear 
gradient of 20-60 % solvent B at a flow rate of 7 mL/min. 
NMR analysis. Samples for NMR spectroscopy contained ~ 0.1 mM peptide dendrimer in 5% 
D2O/95%H2O at pH around 3.5. 1D 1H NMR spectra and 2D 1H-1H TOCSY (mixing time = 80 
ms), NOESY (mixing time = 350 ms), and 1H-13C HSQC NMR spectra were acquired on a 
Bruker AVANCE spectrometer equipped with a cryogenically cooled probe, operating at a 
nominal 1H frequency of 900 MHz. Spectra were acquire at 298 K and the temperature was 
maintained at ± 0.1 K.  
 7 
NE uptake inhibition assay. COS-7 Cells were transiently transfected with NET cDNA using 2 
μg DNA and 10 μl FuGENE per 106 cells at the confluency of 90 %. After 24h culture, 10,000 
cells were evenly distributed per well in a 96-well plate for another 24 hours incubation. An 
average cell count of approximately 50,000 cells per well was counted before uptake assays. A 
fixed concentration of (3H)NE of 30 nM (40.5 Ci/mmol) and increasing concentrations of peptide 
analogues were added into 96-well plates and incubated at 37 °C for 10 min, followed by two 
gentle washes with 100 μl 25 mM HEPES buffer to remove excess (3H)NE. The concentration 
of χ-MrIA dendrimers was calculated based on the dendrimer concentration rather than the 
concentration of the attached χ-MrIA ligand. Cells were then lysed using 50 μl of 0.1 M NaOH 
with gentle shaking for 60 min. Lysed cells were transferred to the flexible 96-well plate with 
Optiphase Supermix scintillant for measurements. Each experiment was performed in triplicate 
and repeated three times.  
Anti-allodynia and motor side effect testing in a rat model of neuropathic pain. Experiments 
were performed on male Sprague Dawley rats (n = 31) weighing 252 +/- 15g on the day of drug 
injections (ARC WA, Perth Australia). Rats were caged in groups of two or three under standard 
conditions with a 12 h light/dark cycle and free access to food and water. A four to five day 
acclimatization period was allowed in the housing facility prior to performing any procedures. 
All procedures were approved by the Royal North Shore Hospital/University of Sydney Animal 
Ethics Committee and followed the Australian Code for the Care and Use of Animals for 
Scientific Purposes (8th edition, 2013). Baseline measurements of mechanical paw withdrawal 
threshold (PWT) and rotarod performance were taken prior to nerve ligation surgery. For 
mechanical PWT rats were acclimatized to clear Perspex chambers, with mesh flooring prior to 
testing. A series of calibrated von Frey filaments 0.4-15.1g (Stoelting, USA) were presented 
using the up-down method.39 If the rat responded to all the filaments, a minimal score of 0.2g 
was assigned. If the rat did not respond to any filaments a maximal score of 15g was assigned. 
An accelerating rotarod (Ugobasile, Italy) was used to measure motor co-ordination. Rats were 
trained to run on the rotarod before baseline measurements were taken. The rats were placed on 
the rotarod and latency to fall was recorded in seconds, with a maximal cut off of 300 seconds. 
Partial ligation of the left sciatic nerve (PNL) was performed on each animal.40 Under isoflurane 
anaesthesia (1.5-4% in oxygen) an incision was made through the skin and muscle at mid-thigh 
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level of the lateral left hind leg. The sciatic nerve was gently isolated from the surrounding 
connective tissue using blunt dissection, and one half to two-thirds of the nerve was ligated with 
6/0 silk suture (Ethicon, USA). Muscle and skin layers were closed using 4/0 and 3/0 silk suture 
(Ethicon, USA) respectively. Intrathecal catheters were placed under isoflurane anaesthesia (1.5-
4% in oxygen) seven to eight days after PNL surgery. A skin incision was made on the dorsal 
midline in the lumbar area. Polyethylene tubing was inserted into the intrathecal space through 
an 18g needle placed in between the fourth and fifth lumbar vertebrae. The tubing was advanced 
three to four centimetres cranially in the intrathecal space.  Correct placement was indicated by 
tail and/or leg twitch when the needle pierced the intrathecal space, and the presence of 
cerebrospinal fluid in the tubing when gently aspirated after placement. The distal end of the 
catheter was tunneled subcutaneously and exteriorized at the level of the neck to prevent self-
removal. After catheter placement the rats were housed individually until the drug injections and 
repeat behavioural tests were performed (maximum of four days). 
On the day of the experiment acclimatization and baseline behavioural measurements were 
performed 30 minutes prior to drug injections and repeated immediately prior to injections 
(time=0 measurement). Drugs were dissolved in 0.9% saline to achieve the required 
concentration, injected in 10µL volumes and flushed through the catheter with 25µL of 0.9% 
saline. A 20nmol dose of each dendrimer (4xMrIA-PEG(9) n = 5, 4xMrIA-PEG(24) n = 5, 
8xMrIA-PEG(24) n = 6) was tested. A 20 nmol dose of MrIA (n=8) was used as a positive 
control, and 0.9% saline (n=7) acted as a negative/vehicle control.  Behavioural measurements 
(von Frey and rotarod) were repeated hourly for four hours after drug injections.  Animals were 
also observed for behavioural side effects throughout the experiment. The experimenter was 
blinded to the drug treatment. Mechanical PWT and rotarod data were analyzed with GraphPad 
Prism 5 (GraphPad Software, San Diego, California, USA) using repeated measures ANOVA, 
followed by Bonferonni post hoc testing when ANOVA was significant. 
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Results and Discussion  
 
Synthesis of alkyne polylysine dendrons and azido χ-MrIA peptides. The lysine-based 
dendrons 2 and 3 and χ-MrIA analogues 4 and 5 possessing alkyne and azido functional groups 
were synthesized using Fmoc solid-phase peptide synthesis (SPPS).41 The dendron scaffold was 
assembled from bis-Fmoc-Lysine as described by Tam,42 taking advantage of the two amino 
groups in each lysine molecules which constitute branching points for exponential growth.11 
GlyArg4Gly residues43 were introduced as a hydrophilic tail to the Rink amide resin to increase 
the solubility of the alkyne modified dendrons and facilitate the MS ionization. By addition of 
further lysine layers we were able to obtain dendrons with 4 and 8 amino groups on the surface, 
which were fully converted into alkyne groups through conjugation with 5-hexynoic acid (Figure 
1). The crude compounds (2 and 3) were subjected to semi-preparative RP-HPLC purification to 
give >90% pure alkyne dendrons (2 and 3), as confirmed by ESI-MS (Figure S1).  
Previous work has demonstrated that the replacement of hydroxyproline with proline residues in 
χ-MrIA is tolerated without loss of binding affinity toward NET.20 Moreover, a truncated 
analogue χ-MrIA with residue asparagine-1 deleted maintained its 3D structure and binding 
affinity comparable to amidated χ-MrIA.20, 31 To avoid the formation of aspartimide,30 the 
truncated χ-MrIA analogue 1, ([Pro]11MrIA[2-13], GVCCGYKLCHPC-NH2, 1-4, 2-3 
connectivity) was used to build the azido-modified χ-MrIA moiety 4 and 5. The azido group was 
introduced to the N-terminus of 1 by coupling of azido-PEG(9)-COOH or azido-PEG(24)-
COOH with chain lengths of approximately 35Å and 90Å respectively. The two PEG chains 
were introduced to increase the solubility of dendrimeric χ-MrIA and more importantly, to assess 
their performance in reducing the steric hindrance for sufficient dendron loading. To ensure 
correct folding of 4 and 5, pairs of Fmoc-cysteine(Acm)-OH and Fmoc-cysteine(Trt)-OH were 
utilized in the synthesis to direct regioselective disulfide bond formation (Figure 2).44 The crude 
peptides were oxidized stepwise, purified after each oxidation step and then subjected to the RP-
HPLC for purification to give >90% pure peptides 4 and 5 (denoted as azido-PEG(9)-
[Pro]11MrIA[2-13] and azido-PEG(24)-[Pro]11MrIA[2-13], respectively) with native (1-4, 2-3) 
disulfide connectivity. (Figure S2). 
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Efficient CuAAc Ligation between alkyne lysine dendrons and azido peptides.  
The CuAAc reaction possesses many properties that distinguish it from alternative coupling 
strategies – these include the rapid rate of reaction and its high chemoselectivity.45 Click reaction 
was herewith selected as the tool for the synthesis of χ-MrIA dendrimers. This was achieved by 
coupling of a 2-fold excess of azido-PEG(9)-[Pro]11MrIA[2-13] peptide 4 per dendrimer arm of 
the alkyne dendron 2 in the presence of CuSO4 and sodium ascorbate as the reducing reagent for 
the formation of the catalytic Cu(I). The tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA) ligand which stabilizes Cu(I) towards disproportionation and oxidation46 was also added 
to the mixture to enhance the Cu(I) catalytic effect. The reaction was monitored by LC ESI-MS 
and a new peak was detected in the LC trace after overnight reaction whereas the alkyne-dendron 
(2) peak disappeared (Figure S3a, b). The reaction mixture was then subjected to semi-
preparative RP-HPLC resulting in a >90% pure tetravalent χ-MrIA dendrimer, referred to as 
4xMrIA-PEG(9)-D (6). Its identity was confirmed by ESI-MS (Figure 3a, Table 1). In order to 
investigate the influence of increasing size and copy number on the χ-MrIA dendrimers on 
pharmacology we attempted to build an 8-mer χ-MrIA dendrimer by click chemistry conjugation 
of dendron 3 with the azido PEG 9-MrIA analogue 4 which resulted disappointingly in a mixture 
of partially decorated χ-MrIA dendrimers with 5, 6, and 7 copies of the χ-MrIA moiety (Figure 
2b).  
The difficulty associated with driving complete decoration with the χ-MrIA analogue possessing 
the PEG 9 spacer was bypassed by elongating the PEG chain from PEG 9 to PEG 24, where the 
steric hindrance in the decoration could be reduced with the longer PEG linker. As expected, the 
fully decorated conjugate of the 8-mer alkyne dendron (3) with azido-PEG(24)-[Pro]11MrIA[2-
13] (5) was readily obtained (Figure S3e, f), providing a pure octavalent χ-MrIA dendrimer 
(denoted as 8xMrIA-PEG(24)-D, 7) with the observed mass consistent with the theoretical one 
(Figure 3c, Table 1). We also designed the 4-mer χ-MrIA dendrimer (denoted as 4xMrIA-
PEG(24)-D, 8) to compare the impact of PEG length on potency (Figure 3d, S3c, d, Table 1).  
2D-NMR structural analysis. NMR is very sensitive to minor local variations in the chemical 
environment and are widely used to detect structural changes for particular parts of molecules.47 
For peptides it is time-consuming to perform a full 3D solution structure determination, hence 
the structural changes are routinely determined by comparing the Hα chemical shifts with 
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chemical shifts derived from random coil values.10 Here, 1D and 2D-NMR spectroscopy at 900 
MHz was employed to characterize the structures of three multivalent χ-MrIA dendrimers (6-8) 
and the truncated analogue [Pro]11MrIA[2-13] (1). For the investigated χ-MrIA dendrimers (6-8) 
only a single set of resonance lines for each attached χ-MrIA moiety was observed in the 
TOCSY, NOESY and HSQC analysis, indicative of free and independent motion of each χ-MrIA 
unit in all dendrimers (6-8). We then compared in detail the structural difference between the χ-
MrIA dendrimers and monomer by assigning and comparing their secondary αH chemical shifts. 
This technique is very sensitive for the detection of structure change48 and the obtained results 
are shown in figure 4a (Table S1-4). These experiments revealed that χ-MrIA-NH231 and 
truncated [Pro]11MrIA [2-13] (1) monomers have very similar αH secondary shifts especially in 
the very important GYKL pharmacophore turn region (Figure 4b), confirming that proline 
substitution has little effect on pharmacophore structure. Additionally, all the copies of χ-MrIA 
analogue presented on dendrimers showed no significant secondary αH shift differences, 
indicative of no change in their structures when compared to the truncated monomer 1 or the χ-
MrIA-NH2 (Figure 4a). Hence, we can conclude that the dendrimer decoration has no influence 
on the secondary structure of χ-MrIA peptide-portion and in particular the GYKL-
pharmacophore region of the peptide. The χ-MrIA dendrimers 6-8 maintain unaltered peptide 
structures that are free to interact with NET independently of each other.  
In vitro and in vivo functional analysis. The in vitro functional activity of χ-MrIA dendrimers 
6-8 and their monomer analogues 4 and 5 were evaluated using a functional human 
norepinephrine transporter assay. As shown in Table 1, the introduction of the azido-PEG chain 
generated active χ-MrIA analogues 4 and 5 with less potency than χ-MrIA-NH2 (Figure 5a, b). 
This loss of affinity was most prominently observed for the PEG(24) peptide 5 compared to the 
PEG(9) peptide 4. This may indicate an interference of the long N-terminal PEG chain on 
transporter binding. In contrast, the χ-MrIA dendrimers 6 and 7 were ~3-fold and ~40-fold more 
potent than their monomeric counterparts, suggesting that the tethered χ-MrIA analogues were 
accessible at the NET binding and possibly cause a slight multivalency. Also, dendrimers 6 and 7 
possessed comparable IC50 values with χ-MrIA-NH2, and thus can be used to mimic the 
bioactivity of χ-MrIA-NH2. Further analysis revealed that for a small dendron like 2 with only 
four χ-MrIA molecules, a short linker of PEG 9 is sufficient (see Table 1, 6) to obtain full 
bioactivity. For the larger dendron with eight peptide molecules surrounding the dendron sphere 
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(7), the PEG(24) resulted in optimum activity equipotent to the χ-MrIA-NH2. On the other hand 
if the chosen PEG chain is too long one might expect an increase of flexibility potentially 
affecting the bioactivity. The elongation of the PEG chain negatively affects the functional 
activity of 8 (small dendron 2 with a long PEG(24) chain) compared to 6 (small dendron 2 with a 
short PEG(9) chain). These findings suggest that for the design of peptide dendrimer that are 
functional, both dendrimer size and linker length need to be optimised.  
After establishment of the in vitro activity of the optimized χ-MrIA dendrimers 6-8, we were 
interested in investigating how the dendrimeric structure might influence the pharmacokinetics in 
a rat pain model of neuropathic pain, which has been extensively used for the validation of the 
duration of action of χ-MrIA analouges.20 The monomer χ-MrIA-NH2 was potent and remained 
anti-nociceptive for up to 3 days after intrathecal administration.49 Given their highly branched 
architectures and increased molecular weights, we had anticipated that the larger dendrimeric χ-
MrIA molecules may show a much more sustained duration in an in vivo pain model. To conduct 
the in vivo test, partial ligation of the sciatic nerve (PNL) was performed, which results in several 
symptoms indicative of neuropathic pain, including marked mechanical allodynia. Mechanical 
paw withdrawal threshold (PWT) measured using calibrated von Frey filaments reduced from 
14.6±1.3g prior to surgery to 1.0±1.2g prior to drug injection at 10-11 days after PNL surgery. χ-
MrIA dendrimers (6-8) and amidated χ-MrIA were then intrathecally administered via chronic 
polyethylene catheters to PNL treated rats. Each compound was administered at a dose of 20 
nmol. As shown in figure 5c, the amidated χ-MrIA compounds resulted in a statistically 
significant (p<0.01) increase in mechanical PWT for four hours after intrathecal injection 
compared to a saline vehicle. Administration of χ-MrIA dendrimers (6-8) did not produce any 
significant differences in PWT in the four hours after injection compared with i.t. injection of a 
saline vehicle. There was no significant difference in rotarod performance between any of the 
drugs or controls (p>0.05) for up to 4 hours post injection (Figure 5d), which suggests the χ-
MrIA dendrimers (6-8) and amidated χ-MrIA did not cause any motor impairment/side-effects. 
A possible explanation of the activity loss in vivo is that χ-MrIA dendrimers are unable to diffuse 
through the spinal cord to reach the NET receptor located in the dorsal horn, the location of the 
descending inhibitory pathway presumed to be the target of the drug.23 These results indicate that 
χ-MrIA dendrimers (6-8) possess no pharmacokinetic advantages compared to free χ-MrIA in an 
intrathecal route of administration. 
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Conclusion 
A comprehensive study of the synthesis, secondary structure and functional activity of χ-MrIA 
dendrimers with sizes 8 KDa to 22 KDa was undertaken. To assemble each dendrimer, azido 
modified χ-MrIA with 2 disulfide bonds was successfully attached to alkyne polylysine-based 
dendrons through optimization of the CuAAc reaction and addition of PEG spacer segment, 
which led to the formation of homogenous tetramer and octamer dendermeric χ-MrIA constructs. 
We demonstrated that variation of linker length and dendron size is necessary to obtain full χ-
MrIA activity though further optimization was not pursued. NMR structural analysis revealed 
that multigeneration lysine-dendrimers did not interfere with the structure of the attached χ-MrIA 
ligands, a key requirement for maintenance of the activity of the structurally sensitive χ-MrIA 
pharmacophore. The functional in vitro activities of the χ-MrIA dendrimers resulted in 
comparable potency at NET with χ-MrIA-NH2 and slightly increased potency when compared to 
azido-PEG-MrIA analogues. In a rat pain study intrathecal in vivo delivery of the peptide 
dendrimer constructs did not lead to pain relief suggesting that χ-MrIA dendrimers of high 
molecular weight are unable to diffuse through the spinal cord to reach the NET receptor located 
in the dorsal horn.23  
 
Supporting Information. Additional data illustrated the LC-ESI-MS results of azido peptides 
and alkyne dendrons, the HPLC reaction monitor traces, NMR 1H, 13C and αH chemical shift 
assignment.  
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Abbreviations  
Natural occurring amino acids are abbreviated to standard single or standard three letter codes; 
HBTU, N,N,N´,N´-tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate); TFA, 
trifluoroacetic acid; DIEA, N,N’-diisopropylethylamine; DMF, N,N’-dimethylformamide; DCM, 
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Dichloromethane; ACN, acetonitrile; HATU, O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate; TBTA, Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine; DMSO, dimethyl sulfoxide; TIPS, triisopropylsilane; PEG, polyethylene 
glycol; CuAAc, copper catalyzed alkyne azide cycloaddition; GPCRs, G-protein coupled 
receptors; χ-conotoxin MrIA (χ-MrIA); RP-HPLC, reversed-phase high-performance liquid 
chromatography; LC-MS, liquid chromatography coupled mass spectrometry; NMR, nuclear 
magnetic resonance; NOESY, nuclear overhauser enhancement spectroscopy; HSQC, 
Heteronuclear single quantum coherence spectroscopy; TOCSY, total correlated spectroscopy; 
NET, norepinephrine transporter; NE, norepinephrine; PWT, paw withdrawal threshold; PNL, 
Partial ligation of the sciatic nerve. 
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Scheme 1. Schematic view of the dendrimeric peptide system (7) which consists of eight 
disulfide-cyclic χ-MrIA analogues N3-PEG(24)-CO-[Pro]11MrIA[2-13] (5) conjugated to a lysine 
dendron core of GlyArg4Gly-Lys[Lys]2[Lys]4[CO-(CH2)3-CCH]8 (3) by employing copper 
catalyzed azide-alkyne click chemistry.  
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Figure 1. Synthesis route of alkyne modified 4-mer and 8-mer polylysine dendrons (2 and 3) 
employing coupling of 2 and 3 generations respectively of bis-Fmoc-Lysine onto a Gly-Arg4-Gly 
anchor. Polylysine dendrons were armed for click chemistry by modification with 5-Hexynoic 
acid.   
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Figure 2. Synthesis route of azido PEG chain modified χ-MrIA analogues (4 and 5) employing 
Fmoc-SPPS with stepwise selective disulfide bond formation using orthogonal Cys(Trt) and 
Cys(Acm) protection  
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Figure 3. LC-MS results for the synthesis of a) 4xMrIA-PEG(9)-D (6), b) χ-MrIA dendrimer 
mixture obtained from click reaction of 3 and 4 showing insufficient decoration with 5, 6, and 7 
attached χ-MrIA units, c) 8xMrIA-PEG(24)-D (7) and d) 4xMrIA-PEG(24)-D (8). 
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Figure 4. a) Secondary -shifts of χ-MrIA-NH2,31 [Pro]11MrIA-NH2[2-13] (1) and χ-MrIA 
dendrimers (6-8). The secondary shifts were determined by subtracting the random coil shift50 
from the αH shift; b) NMR structure of native χ-MrIA highlighting the pharmacophore 
located within residues Gly6, Tyr7, Lys8 and Leu9 of this class of norepinephrine reuptake 
inhibitor.20 Secondary -shifts confirmed the structural integrity of the attached peptide 
molecules and pharmacophore region Gly6 to Leu9. 
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Figure 5. a) Functional norepinephrine reuptake assay of the χ-MrIA dendrimers (6-8), 
monomer azide analogues (4 and 5) and χ-MrIA-NH2. Representative concentration-response 
curves performed in triplicate for each sample; b) comparison of pIC50 values of χ-MrIA 
dendrimers (6-8), monomer analogue (4 and 5) and χ-MrIA-NH2 obtained from NE uptake 
inhibition assay. Data are presented as mean ± SEM of n = 3 replicates and are 
representative of 3 independent experiments; c) in vivo rat pain model: the mean (±SEM) von 
Frey threshold versus time curves for the relief of mechanical allodynia produced by i.t. 
administration of 20 nmol of each χ-MrIA dendrimer (6-8), amidated χ-MrIA as a positive 
control and 0.9% saline as a negative/vehicle control in PNL treated rats; d) Central effect 
assessment: rotarod performance of the χ-MrIA dendrimers (6-8), amidated χ-MrIA and 0.9% 
saline in PNL treated rats. 4xMrIA-PEG(9)-D n = 5, 4xMrIA-PEG(24)-D n = 5, 8xMrIA-
PEG(24)-D n = 6, χ-MrIA-NH2 (n=8) and 0.9% saline (n=7). 
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Table 1. ESI-MS analysis of 2-8 and norepinephrine reuptake inhibition (IC50) by azido-PEG-
[Pro]11MrIA[2-13]-NH2 (4 and 5), χ-MrIA dendrimers (6-8) and χ-MrIA-NH2 (1–4, 2–3 disulfide 
bond). IC50 values are means ± SEM of 3 separate experiments (performed in triplicate). 
[a] IC50 value of χ-MrIA-NH2 measured in literature29.  
 
 
 
No. Analogue Calculated 
MW (Da) 
Observed 
MW (Da) 
IC50 (μM) 
 
χ-MrIA-NH2 
  
3.0 ± 0.5 
2.45 ± 0.07[a] 
2 4-mer alkyne dendron 1516.6 1516.4 - 
3 8-mer alkyne dendron 2405.9 2406.4 - 
4 N3-PEG(9)-[Pro]11MrIA[2-13]-NH2 1813.5 1813.0 7.8 ± 0.5 
5 N3-PEG(24)-[Pro]11MrIA[2-13]-NH2 2432.5 2432.0 96.5 ± 1.5 
6 4xMrIA-PEG(9)-D 8770.6 879.8 2.5 ± 0.2 
7 8xMrIA-PEG(24)-D 21865.9 21865.4 2.3 ± 0.5 
8 4xMrIA-PEG(24)-D 11246.4 11246.4 12 ± 0.09 
